BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guisier F, Dubos-arvis C, Viñas F, Doubre H, Ricordel C, Ropert S, Janicot H, Bernardi M, Fournel P, Lamy R, Pérol M, Dauba J, Gonzales G, Falchero L, Decroisette C, Assouline P, Chouaid C, Bylicki O. Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018. Journal of Thoracic Oncology 2020;15:628-36. [DOI: 10.1016/j.jtho.2019.12.129] [Cited by in Crossref: 49] [Cited by in F6Publishing: 59] [Article Influence: 24.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu C, Lu M, Yang Y, Wang X, Ma F, Liu X. Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation. Front Oncol 2022;12:961539. [DOI: 10.3389/fonc.2022.961539] [Reference Citation Analysis]
2 Pisapia P, Iaccarino A, De Luca C, Acanfora G, Bellevicine C, Bianco R, Daniele B, Ciampi L, De Felice M, Fabozzi T, Formisano L, Giordano P, Gridelli C, Ianniello GP, Libroia A, Maione P, Nacchio M, Pagni F, Palmieri G, Pepe F, Russo G, Salatiello M, Santaniello A, Scamarcio R, Seminati D, Troia M, Troncone G, Vigliar E, Malapelle U. Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy. IJMS 2022;23:8541. [DOI: 10.3390/ijms23158541] [Reference Citation Analysis]
3 Gy Lai G, Guo R, Drilon A, Shao Weng Tan D. Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102444] [Reference Citation Analysis]
4 De Felice M, Pisapia P, Pepe F, De Luca C, Iaccarino A, Malapelle U, Troncone G, Ianniello GP. Unusual Clinical Experience in BRAF Exon 15 p.K601E-Mutated Lung Cancer: A Case Report and Brief Review of the Literature. Applied Sciences 2022;12:7552. [DOI: 10.3390/app12157552] [Reference Citation Analysis]
5 Zhang L, Zheng L, Yang Q, Sun J. The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer. Front Oncol 2022;12:882940. [DOI: 10.3389/fonc.2022.882940] [Reference Citation Analysis]
6 López-Castro R, García-Peña T, Mielgo-Rubio X, Riudavets M, Teixidó C, Vilariño N, Couñago F, Mezquita L. Targeting molecular alterations in non-small-cell lung cancer: what's next? Per Med 2022. [PMID: 35748237 DOI: 10.2217/pme-2021-0059] [Reference Citation Analysis]
7 Hata T, Sakaguchi C, Hirano K, Kobe H, Ishida M, Nakano T, Tachibana Y, Tamiya N, Shiotsu S, Takeda T, Yamada T, Yokoyama T, Tsuchiya M, Nagasaka Y. Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study. J Cancer Res Clin Oncol 2022. [PMID: 35737092 DOI: 10.1007/s00432-022-04125-8] [Reference Citation Analysis]
8 Illini O, Fabikan H, Swalduz A, Vikström A, Krenbek D, Schumacher M, Dudnik E, Studnicka M, Öhman R, Wurm R, Wannesson L, Peled N, Kian W, Bar J, Daher S, Addeo A, Rotem O, Pall G, Zer A, Saad A, Cufer T, Sorotsky HG, Hashemi SMS, Mohorcic K, Stoff R, Rovitsky Y, Keren-Rosenberg S, Winder T, Weinlinger C, Valipour A, Hochmair MJ. Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program. Ther Adv Med Oncol 2022;14:17588359221103206. [PMID: 35720834 DOI: 10.1177/17588359221103206] [Reference Citation Analysis]
9 Bodor JN, Bauman JR, Handorf EA, Ross EA, Clapper ML, Treat J. Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy. J Cancer Res Clin Oncol 2022. [PMID: 35708776 DOI: 10.1007/s00432-022-04089-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Meng Y, Yang Y, Fang Y, Lin X, Xie X, Deng H, Wu J, Zhou M, Sun N, Xie Z, Liu M, Ouyang M, Qin Y, Su C, Zhou C. The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research. Front Oncol 2022;12:864367. [PMID: 35692799 DOI: 10.3389/fonc.2022.864367] [Reference Citation Analysis]
11 Tian T, Yu M, Yu Y, Wang K, Tian P, Luo Z, Ding Z, Wang Y, Gong Y, Zhu J, Zou B, Sio TT, Alves A, Liu Y, Huang M, Lu Y. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study. Transl Lung Cancer Res 2022;11:1027-37. [PMID: 35832458 DOI: 10.21037/tlcr-22-376] [Reference Citation Analysis]
12 Wang D, Chen X, Du Y, Li X, Ying L, Lu Y, Shen B, Gao X, Yi X, Xia X, Sui X, Shu Y. Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors. Front Immunol 2022;13:799988. [PMID: 35281032 DOI: 10.3389/fimmu.2022.799988] [Reference Citation Analysis]
13 Uehara Y, Watanabe K, Hakozaki T, Yomota M, Hosomi Y. Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS , MET , FGFR , RET , BRAF , and HER2 alterations. Thoracic Cancer. [DOI: 10.1111/1759-7714.14448] [Reference Citation Analysis]
14 Riudavets M, Cascetta P, Planchard D. Targeting BRAF-mutant non-small cell lung cancer: current status and future directions. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.05.014] [Reference Citation Analysis]
15 Masuda T, Fujitaka K, Suzuki T, Hamai K, Matsumoto N, Matsumura M, Isoyama S, Ueno S, Mito M, Yamaguchi K, Sakamoto S, Kawano R, Masuda K, Nishino R, Ishikawa N, Yamasaki M, Hattori N. Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1. Thorac Cancer 2022. [PMID: 35488720 DOI: 10.1111/1759-7714.14428] [Reference Citation Analysis]
16 Yu X, Ji X, Su C. HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies. Front Oncol 2022;12:860313. [PMID: 35425713 DOI: 10.3389/fonc.2022.860313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Yan N, Guo S, Zhang H, Zhang Z, Shen S, Li X. BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective. Front Oncol 2022;12:863043. [DOI: 10.3389/fonc.2022.863043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Abu Rous F, Gutta R, Li P, Halmos B, Gadgeel S. Pembrolizumab in Combination with Chemotherapy in Patients with ERBB2-Mutated Non-Small Cell Lung Cancer. Targ Oncol. [DOI: 10.1007/s11523-022-00873-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Cefalì M, Epistolio S, Ramelli G, Mangan D, Molinari F, Martin V, Freguia S, Mazzucchelli L, Froesch P, Frattini M, Wannesson L. Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy. J Clin Med 2022;11:1627. [PMID: 35329953 DOI: 10.3390/jcm11061627] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Knetki-Wróblewska M, Wojas-Krawczyk K, Kowalski DM, Krzakowski M. Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion-Which Path Should We Follow? Case Reports and Literature Review. J Clin Med 2022;11:1630. [PMID: 35329956 DOI: 10.3390/jcm11061630] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Yang G, Yang Y, Liu R, Li W, Xu H, Hao X, Li J, Xing P, Zhang S, Ai X, Xu F, Wang Y. First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2 -altered NSCLC: a retrospective real-world POLISH study. Ther Adv Med Oncol 2022;14:175883592210823. [DOI: 10.1177/17588359221082339] [Reference Citation Analysis]
22 Tabbò F, Pisano C, Mazieres J, Mezquita L, Nadal E, Planchard D, Pradines A, Santamaria D, Swalduz A, Ambrogio C, Novello S, Ortiz-cuaran S. How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC). Cancer Treatment Reviews 2022;103:102335. [DOI: 10.1016/j.ctrv.2021.102335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
23 Gendarme S, Bylicki O, Chouaid C, Guisier F. ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date. Current Oncology 2022;29:641-58. [DOI: 10.3390/curroncol29020057] [Reference Citation Analysis]
24 Murciano-goroff YR, Pak T, Mondaca S, Flynn JR, Montecalvo J, Rekhtman N, Halpenny D, Plodkowski AJ, Wu SL, Kris MG, Paik PK, Riely GJ, Yu HA, Rudin CM, Hellmann MD, Land JD, Buie LW, Heller G, Lito P, Yaeger R, Drilon A, Liu D, Li BT, Offin M. Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. Br J Cancer. [DOI: 10.1038/s41416-021-01679-1] [Reference Citation Analysis]
25 Seegobin K, Majeed U, Wiest N, Manochakian R, Lou Y, Zhao Y. Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR. Front Oncol 2021;11:750657. [PMID: 34926258 DOI: 10.3389/fonc.2021.750657] [Reference Citation Analysis]
26 Vathiotis IA, Charpidou A, Gavrielatou N, Syrigos KN. HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy. Pharmaceuticals 2021;14:1300. [DOI: 10.3390/ph14121300] [Reference Citation Analysis]
27 Riudavets M, Naigeon M, Texier M, Dorta M, Barlesi F, Mazieres J, Varga A, Cassard L, Boselli L, Grivel J, Ngocamus M, Lacroix L, Mezquita L, Besse B, Chaput N, Planchard D. Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial. Lung Cancer 2021. [DOI: 10.1016/j.lungcan.2021.11.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Holtzman L, Moskovitz M, Urban D, Nechushtan H, Keren S, Reinhorn D, Wollner M, Daher S, Rottenberg Y, Rovitzky Y, Shochat T, Bar J, Dudnik E. dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%. Clinical Lung Cancer 2021. [DOI: 10.1016/j.cllc.2021.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Chu X, Qiang H, Xie M, Li X, Zhao J, Wu Y, Zhou J, Ye J, Zhao C, Han C, Chu T, Su C. Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study. Cancer Immunol Immunother 2021. [PMID: 34743223 DOI: 10.1007/s00262-021-03100-5] [Reference Citation Analysis]
30 Su S, Lin A, Luo P, Zou J, Huang Z, Wang X, Zeng Y, Cen W, Zhang X, Huang H, Hu J, Zhang J. Effect of mesenchymal-epithelial transition amplification on immune microenvironment and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer. Ann Transl Med 2021;9:1475. [PMID: 34734027 DOI: 10.21037/atm-21-4543] [Reference Citation Analysis]
31 Li N, Xu Y, Fan Y. [Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant 
Advanced Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2021;24:714-22. [PMID: 34696543 DOI: 10.3779/j.issn.1009-3419.2021.101.29] [Reference Citation Analysis]
32 Deng Z, Cui L, Li P, Ren N, Zhong Z, Tang Z, Wang L, Gong J, Cheng H, Guan Y, Yi X, Xia X, Zhou R, He Z. Genomic comparison between cerebrospinal fluid and primary tumor revealed the genetic events associated with brain metastasis in lung adenocarcinoma. Cell Death Dis 2021;12:935. [PMID: 34642306 DOI: 10.1038/s41419-021-04223-4] [Reference Citation Analysis]
33 Gavralidis A, Gainor JF. Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer: Implications for Oncogene-Driven Lung Cancer. Cancer J 2020;26:517-24. [PMID: 33298723 DOI: 10.1097/PPO.0000000000000491] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
34 Friedlaender A, Subbiah V, Russo A, Banna GL, Malapelle U, Rolfo C, Addeo A. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nat Rev Clin Oncol 2021. [PMID: 34561632 DOI: 10.1038/s41571-021-00558-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Riudavets M, Sullivan I, Abdayem P, Planchard D. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open 2021;6:100260. [PMID: 34479034 DOI: 10.1016/j.esmoop.2021.100260] [Reference Citation Analysis]
36 Planchard D, Besse B, Groen HJM, Hashemi SMS, Mazieres J, Kim TM, Quoix E, Souquet PJ, Barlesi F, Baik C, Villaruz LC, Kelly RJ, Zhang S, Tan M, Gasal E, Santarpia L, Johnson BE. Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. J Thorac Oncol 2021:S1556-0864(21)02403-5. [PMID: 34455067 DOI: 10.1016/j.jtho.2021.08.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 15.0] [Reference Citation Analysis]
37 Drusbosky LM, Dawar R, Rodriguez E, Ikpeazu CV. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer. J Hematol Oncol 2021;14:129. [PMID: 34425853 DOI: 10.1186/s13045-021-01138-7] [Reference Citation Analysis]
38 Lee J, Ahn MJ. Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer: is there a role? Curr Opin Oncol 2021;33:64-72. [PMID: 33186183 DOI: 10.1097/CCO.0000000000000698] [Reference Citation Analysis]
39 Tian P, Zeng H, Ji L, Ding Z, Ren L, Gao W, Fan Z, Li L, Le X, Li P, Zhang M, Xia X, Zhang J, Li Y, Li W. Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy. Lung Cancer 2021;160:50-8. [PMID: 34403912 DOI: 10.1016/j.lungcan.2021.07.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Bittoni M, Yang JC, Shih JY, Peled N, Smit EF, Camidge DR, Arasada RR, Oksen D, Boutmy E, Stroh C, Johne A, Carbone DP, Paik PK. Real-world insights into patients with advanced NSCLC and MET alterations. Lung Cancer 2021;159:96-106. [PMID: 34320421 DOI: 10.1016/j.lungcan.2021.06.015] [Reference Citation Analysis]
41 Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol 2021. [PMID: 34168333 DOI: 10.1038/s41571-021-00520-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Lin J, Wang X, Zhang C, Bu S, Zhao C, Wang H. A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab. Front Immunol 2021;12:606027. [PMID: 34248926 DOI: 10.3389/fimmu.2021.606027] [Reference Citation Analysis]
43 Chiu LC, Lin SM, Lo YL, Kuo SC, Yang CT, Hsu PC. Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). Vaccines (Basel) 2021;9:689. [PMID: 34201650 DOI: 10.3390/vaccines9070689] [Reference Citation Analysis]
44 Bhandari NR, Hess LM, Han Y, Zhu YE, Sireci AN. Efficacy of immune checkpoint inhibitor therapy in patients with RET fusion-positive non-small-cell lung cancer. Immunotherapy 2021;13:893-904. [PMID: 34139897 DOI: 10.2217/imt-2021-0035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Baby S, Khalil F, Tanvetyanon T. Frontline pembrolizumab for the treatment of RET-rearranged non-small cell lung cancer: A case report. Cancer Treat Res Commun 2021;28:100423. [PMID: 34166867 DOI: 10.1016/j.ctarc.2021.100423] [Reference Citation Analysis]
46 Davis AP, Cooper WA, Boyer M, Lee JH, Pavlakis N, Kao SC. Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations. Immunotherapy 2021;13:941-52. [PMID: 34114474 DOI: 10.2217/imt-2021-0090] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Dantoing E, Piton N, Salaün M, Thiberville L, Guisier F. Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations. Int J Mol Sci 2021;22:6288. [PMID: 34208111 DOI: 10.3390/ijms22126288] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Chi A, He X, Hou L, Nguyen NP, Zhu G, Cameron RB, Lee JM. Classification of Non-Small Cell Lung Cancer's Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade. Cancers (Basel) 2021;13:2924. [PMID: 34208113 DOI: 10.3390/cancers13122924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Guaitoli G, Tiseo M, Di Maio M, Friboulet L, Facchinetti F. Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis. Transl Lung Cancer Res 2021;10:2890-916. [PMID: 34295687 DOI: 10.21037/tlcr-20-941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Duchemann B, Remon J, Naigeon M, Cassard L, Jouniaux JM, Boselli L, Grivel J, Auclin E, Desnoyer A, Besse B, Chaput N. Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer. Transl Lung Cancer Res 2021;10:2937-54. [PMID: 34295689 DOI: 10.21037/tlcr-20-839] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Zeng J, Ma W, Young RB, Li T. Targeting HER2 genomic alterations in non-small cell lung cancer. Journal of the National Cancer Center 2021;1:58-73. [DOI: 10.1016/j.jncc.2021.04.001] [Reference Citation Analysis]
52 McLean L, Leal JL, Solomon BJ, John T. Immunotherapy in oncogene addicted non-small cell lung cancer. Transl Lung Cancer Res 2021;10:2736-51. [PMID: 34295674 DOI: 10.21037/tlcr-20-772] [Reference Citation Analysis]
53 Li T, Pang X, Wang J, Wang S, Guo Y, He N, Xing P, Li J. Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR-Mutant Lung Adenocarcinoma. Front Oncol 2021;11:591922. [PMID: 34136375 DOI: 10.3389/fonc.2021.591922] [Reference Citation Analysis]
54 Liu SY, Wu YL. Unmet Clinical Demand for Patients With Unresectable Stage III NSCLC Having Actionable Genetic Alterations. J Thorac Oncol 2021;16:712-4. [PMID: 33896568 DOI: 10.1016/j.jtho.2021.02.020] [Reference Citation Analysis]
55 Fujino T, Suda K, Mitsudomi T. Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges. Lung Cancer (Auckl) 2021;12:35-50. [PMID: 34295201 DOI: 10.2147/LCTT.S269307] [Reference Citation Analysis]
56 Taha T, Khoury R, Brenner R, Nasrallah H, Shofaniyeh I, Yousef S, Agbarya A. Treatment of Rare Mutations in Patients with Lung Cancer. Biomedicines 2021;9:534. [PMID: 34064757 DOI: 10.3390/biomedicines9050534] [Reference Citation Analysis]
57 El Husseini K, Wislez M. Sequential or combined immune checkpoint inhibitors and targeted therapy: Navigating uncharted waters. Respir Med Res 2021;79:100820. [PMID: 33892315 DOI: 10.1016/j.resmer.2021.100820] [Reference Citation Analysis]
58 Addeo A, Passaro A, Malapelle U, Luigi Banna G, Subbiah V, Friedlaender A. Immunotherapy in non-small cell lung cancer harbouring driver mutations. Cancer Treat Rev 2021;96:102179. [PMID: 33798954 DOI: 10.1016/j.ctrv.2021.102179] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
59 De Toma A, Lo Russo G, Signorelli D, Pagani F, Randon G, Galli G, Prelaj A, Ferrara R, Proto C, Ganzinelli M, Zilembo N, de Braud F, Garassino MC. Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. Crit Rev Oncol Hematol 2021;160:103299. [PMID: 33722699 DOI: 10.1016/j.critrevonc.2021.103299] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Huang RSP, Severson E, Haberberger J, Duncan DL, Hemmerich A, Edgerly C, Ferguson NL, Frampton G, Owens C, Williams E, Elvin J, Vergilio JA, Killian JK, Lin D, Morley S, McEwan D, Holmes O, Danziger N, Cohen MB, Sathyan P, McGregor K, Reddy P, Venstrom J, Anhorn R, Alexander B, Brown C, Ross JS, Ramkissoon SH. Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry. Pathol Oncol Res 2021;27:592997. [PMID: 34257540 DOI: 10.3389/pore.2021.592997] [Reference Citation Analysis]
61 Rebuzzi SE, Zullo L, Rossi G, Grassi M, Murianni V, Tagliamento M, Prelaj A, Coco S, Longo L, Dal Bello MG, Alama A, Dellepiane C, Bennicelli E, Malapelle U, Genova C. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. Int J Mol Sci 2021;22:2625. [PMID: 33807876 DOI: 10.3390/ijms22052625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Fancelli S, Caliman E, Mazzoni F, Brugia M, Castiglione F, Voltolini L, Pillozzi S, Antonuzzo L. Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives. Cancers (Basel) 2021;13:1091. [PMID: 33806299 DOI: 10.3390/cancers13051091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Kato Y, Yamamoto G, Watanabe Y, Yamane Y, Mizutani H, Kurimoto F, Seike M, Gemma A, Akagi K, Sakai H. Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations. Int J Clin Oncol 2021;26:1065-72. [PMID: 33660106 DOI: 10.1007/s10147-021-01893-0] [Reference Citation Analysis]
64 Niu M, Yi M, Li N, Luo S, Wu K. Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC. Exp Hematol Oncol 2021;10:18. [PMID: 33653420 DOI: 10.1186/s40164-021-00211-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
65 Jia Z, Xing J, Li J, Wang W, Wang Y, Song Y, Yang X, Xue J, Ye J, Li B, Han-Zhang H, Zhao J, Zhang X, Peng F, Chen F, Chen X, Lu Y, Ying S, Wu D, Zhang X, Ma C, Lai L, Ma S, Liang D, Liu P, Li X, Liang N, Li S. HER2 transmembrane domain mutation: comprehensive characteristics and real-world evidence of treatment response in Chinese lung adenocarcinoma. Transl Lung Cancer Res 2021;10:1383-96. [PMID: 33889517 DOI: 10.21037/tlcr-21-107] [Reference Citation Analysis]
66 Wenzel C, Herold S, Saalfeld FC, Aust DE, Wermke M. The clinical benefit of molecular re-assessments in management of progressive lung cancer. Transl Lung Cancer Res 2021;10:1582-7. [PMID: 33889532 DOI: 10.21037/tlcr-20-996] [Reference Citation Analysis]
67 Choudhury NJ, Drilon A. Decade in review: a new era for RET-rearranged lung cancers. Transl Lung Cancer Res 2020;9:2571-80. [PMID: 33489819 DOI: 10.21037/tlcr-20-346] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
68 Li T, Li J. [Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer 
with Rare Mutation]. Zhongguo Fei Ai Za Zhi 2021;24:19-24. [PMID: 33478186 DOI: 10.3779/j.issn.1009-3419.2020.102.41] [Reference Citation Analysis]
69 Lau SCM, Fares AF, Le LW, Mackay KM, Soberano S, Chan SW, Smith E, Ryan M, Tsao MS, Bradbury PA, Pal P, Shepherd FA, Liu G, Leighl NB, Sacher AG. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors. Clin Lung Cancer 2021;22:253-9. [PMID: 33582070 DOI: 10.1016/j.cllc.2020.12.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
70 Calles A, Riess JW, Brahmer JR. Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely. Am Soc Clin Oncol Educ Book 2020;40:372-84. [PMID: 32421452 DOI: 10.1200/EDBK_280795] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
71 Hess LM, Han Y, Zhu YE, Bhandari NR, Sireci A. Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States. BMC Cancer 2021;21:28. [PMID: 33402119 DOI: 10.1186/s12885-020-07714-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
72 Nokin MJ, Ambrogio C, Nadal E, Santamaria D. Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer. Trends Cancer 2021;7:410-29. [PMID: 33309239 DOI: 10.1016/j.trecan.2020.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
73 Auliac JB, Bayle S, Do P, Le Garff G, Roa M, Falchero L, Huchot E, Quéré G, Jeannin G, Métivier AC, Hobeika J, Guisier F, Chouaid C. Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019. Cancers (Basel) 2020;12:E3608. [PMID: 33276639 DOI: 10.3390/cancers12123608] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Leone G, Passiglia F, Bironzo P, Bertaglia V, Novello S. Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?-a literature review. Transl Lung Cancer Res 2020;9:2674-85. [PMID: 33489826 DOI: 10.21037/tlcr-20-710] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Solomon BJ, Zhou CC, Drilon A, Park K, Wolf J, Elamin Y, Davis HM, Soldatenkova V, Sashegyi A, Lin AB, Lin BK, F Loong HH, Novello S, Arriola E, Pérol M, Goto K, Santini FC. Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer. Future Oncol 2021;17:763-73. [PMID: 33150799 DOI: 10.2217/fon-2020-0935] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
76 Zhao J, Xia Y. Reply to G. Sartori et al. JCO Precis Oncol 2020;4:1052-3. [PMID: 35050768 DOI: 10.1200/PO.20.00258] [Reference Citation Analysis]
77 Rittberg R, Banerji S, Green S, Qing G, Dawe DE. Immunotherapy Benefit in a Patient With Non-Small Cell Lung Cancer and a Rare BRAF Mutation. Cureus 2020;12:e11224. [PMID: 33269152 DOI: 10.7759/cureus.11224] [Reference Citation Analysis]
78 Riudavets M, Caramella C, Pradere P, Naltet C, Le Pechoux C, Adam J, Mabille L, Rouleau E, Besse B, Planchard D. Complete, Unpredictable, Multi-site Response Including Brain and Liver Metastases in a Patient With RET-rearranged Non-small-cell Lung Cancer Treated With Single-agent Immunotherapy: A Case Report. Clin Lung Cancer 2021;22:e215-9. [PMID: 33187915 DOI: 10.1016/j.cllc.2020.10.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 O'Donnell JC, Le TK, Dobrin R, Higashi M, Pereira A, Wagner S, Yang A, Hukkelhoven M. Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes. Future Oncol 2021;17:333-47. [PMID: 33074018 DOI: 10.2217/fon-2020-0591] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Malapelle U, Rossi G, Pisapia P, Barberis M, Buttitta F, Castiglione F, Cecere FL, Grimaldi AM, Iaccarino A, Marchetti A, Massi D, Medicina D, Mele F, Minari R, Orlando E, Pagni F, Palmieri G, Righi L, Russo A, Tommasi S, Vermi W, Troncone G. BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients. Crit Rev Oncol Hematol 2020;156:103118. [PMID: 33038627 DOI: 10.1016/j.critrevonc.2020.103118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
81 Lamberti G, Andrini E, Sisi M, Rizzo A, Parisi C, Di Federico A, Gelsomino F, Ardizzoni A. Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. Crit Rev Oncol Hematol 2020;156:103119. [PMID: 33053439 DOI: 10.1016/j.critrevonc.2020.103119] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
82 Mayenga M, Assié JB, Monnet I, Massiani MA, Tabeze L, Friard S, Fraboulet S, Métivier AC, Chouaïd C, Zemoura L, Longchampt E, Callens C, Melaabi S, Couderc LJ, Doubre H. Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases. Lung Cancer 2020;150:21-5. [PMID: 33045465 DOI: 10.1016/j.lungcan.2020.09.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
83 Fujino T, Suda K, Mitsudomi T. Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Expert Opin Emerg Drugs 2020;25:229-49. [PMID: 32615820 DOI: 10.1080/14728214.2020.1791821] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
84 Zhou J, Ding N, Xu X, Zhang Y, Ye M, Li C, Hu J. Clinical outcomes of patients with HER2-mutant advanced lung cancer: chemotherapies versus HER2-directed therapies. Ther Adv Med Oncol 2020;12:1758835920936090. [PMID: 32647540 DOI: 10.1177/1758835920936090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Bylicki O, Paleiron N, Assié JB, Chouaïd C. Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date. Onco Targets Ther 2020;13:5691-706. [PMID: 32606781 DOI: 10.2147/OTT.S219959] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
86 Frisone D, Friedlaender A, Malapelle U, Banna G, Addeo A. A BRAF new world. Crit Rev Oncol Hematol. 2020;152:103008. [PMID: 32485528 DOI: 10.1016/j.critrevonc.2020.103008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
87 Wu Y, Ni J, Chang X, Zhang X, Zhang L. Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non-small-cell lung cancer and ERBB2 mutation. Thorac Cancer 2020;11:2051-5. [PMID: 32458584 DOI: 10.1111/1759-7714.13480] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
88 Baglivo S, Ludovini V, Moretti R, Bellezza G, Sidoni A, Roila F, Metro G. RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature. Oncol Ther 2020;8:333-9. [PMID: 32700042 DOI: 10.1007/s40487-020-00116-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
89 Osta BE, Ramalingam SS. RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC. JTO Clin Res Rep 2020;1:100050. [PMID: 34589946 DOI: 10.1016/j.jtocrr.2020.100050] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
90 Facchinetti F, Lacroix L, Mezquita L, Scoazec JY, Loriot Y, Tselikas L, Gazzah A, Rouleau E, Adam J, Michiels S, Massard C, André F, Olaussen KA, Vassal G, Howarth K, Besse B, Soria JC, Friboulet L, Planchard D. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer. Eur J Cancer 2020;132:211-23. [PMID: 32388065 DOI: 10.1016/j.ejca.2020.03.025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
91 Li YH, Hu YQ, Wang SC, Li Y, Chen DM. LncRNA SNHG5: A new budding star in human cancers. Gene 2020;749:144724. [PMID: 32360843 DOI: 10.1016/j.gene.2020.144724] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
92 Eguren-Santamaria I, Sanmamed MF, Gil-Bazo I. Are Immune Checkpoint Inhibitors Effective Against Uncommon Oncogene-Driven NSCLC Subtypes? J Thorac Oncol 2020;15:489-92. [PMID: 32216943 DOI: 10.1016/j.jtho.2020.02.003] [Reference Citation Analysis]
93 Zhang T, Li B. [Application Progress of Immune Checkpoint Inhibitors 
in Oncogene-driven Advanced Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2021;24:188-95. [PMID: 33819969 DOI: 10.3779/j.issn.1009-3419.2021.101.04] [Reference Citation Analysis]